Ulcerative colitis.

@article{Danese2011UlcerativeC,
  title={Ulcerative colitis.},
  author={S. Danese and C. Fiocchi},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 18},
  pages={
          1713-25
        }
}
 Is medical clearance required? .................................. Possibly (e.g., if the disease is unstable — flare-up — and/or there are active oral lesions). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/increased risk of infection (e.g., corticosteroids [e.g., prednisone], azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, sulfasalazine, biologic response modifier drugs [e.g., anti-tumour necrosis… Expand
View on PubMed
cdho.org
196 Citations
Highly Influential Citations
11
Background Citations
113
Methods Citations
4
Results Citations
2

196 Citations

Citation Type

Citation Type

Biological Agents for Moderately to Severely Active Ulcerative Colitis
Immunosuppressive and biologic therapy for ulcerative colitis
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
Inflammatory pathways of importance for management of inflammatory bowel disease.
Skin Manifestations of Inflammatory Bowel Disease
Ulcerative Colitis: Update on Medical Management
Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.
Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
  • B. Feagan, D. Rubin, +5 authors M. Smyth
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?
Exacerbation of ulcerative colitis after rituximab salvage therapy
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Biological therapies for inflammatory bowel diseases.
European evidence-based Consensus on the management of ulcerative colitis: Current management.
Diagnostic Standards in the Pathology of Inflammatory Bowel Disease
Colectomy rate in acute severe ulcerative colitis in the infliximab era.
  • A. Aratari, C. Papi, +5 authors R. Caprilli
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2008
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
  • S. Hanauer
  • Medicine
  • Nature Clinical Practice Gastroenterology &Hepatology
  • 2004
Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production
Inflammatory bowel disease: the role of environmental factors.
...
1
2
3
4
5
...